Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
telehomecare · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| telehomecare | DEVICE | - |
Inclusion Criteria: * clinical diagnosis of congestive heart failure * must have telephone line in home Exclusion Criteria: * none
Telehomecare is an investigational intervention being studied for use in patients with Congestive Heart Failure. It is designed to support disease management through technology-based remote care. The intervention is currently in Phase 1 clinical development and has not been approved by regulatory authorities. Its use in this condition is still being evaluated in clinical trials.
Telehomecare is being developed by Johnson & Johnson, a company publicly traded under the ticker symbol JNJ. The company is conducting clinical research to evaluate the intervention for Congestive Heart Failure. As of the available data, telehomecare is in Phase 1 development and remains investigational.
Telehomecare is currently in Phase 1 clinical development. It is an investigational intervention for Congestive Heart Failure and has not been approved by the FDA or any other regulatory body. The Phase 1 trial has been completed, and the intervention is still in the early stages of clinical evaluation.
Telehomecare has been studied in one completed clinical trial with the identifier NCT00261664, titled 'Empowering Elders Through Technology.' This Phase 1 trial enrolled 290 participants with Congestive Heart Failure in the United States. The trial was not blinded and did not use a control group, and it has been completed.
No alternative names for telehomecare have been identified in the available information. The intervention is referred to solely as telehomecare in the context of its clinical development for Congestive Heart Failure. It is an investigational technology-based intervention being developed by Johnson & Johnson.